FDA and FTC warned Dr. Paul's Lab over selling unapproved COVID-Aid Tincture with claims to prevent or treat COVID-19.
What happened
FDA reviewed drpaulslab.net on January 28, 2021, and FTC reviewed it on February 9, 2021. The website directed consumers to dealers, including drsarahsessentials.com, which offered "COVID-Aid Tincture" for sale in the U.S. FDA found the product was intended to mitigate, prevent, treat, diagnose, or cure COVID-19, citing label directions telling users to take 1 cc under the tongue 4–6 times daily if illness was suspected.
What FDA found
The product is an unapproved new drug because it is intended to treat or prevent COVID-19 without FDA approval.
section 505(a) of the FD&C Act, 21 U.S.C. § 355(a)The product is misbranded because its labeling makes misleading COVID-19 claims.
section 502 of the FD&C Act, 21 U.S.C. § 352The company is prohibited from introducing the product into interstate commerce.
sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)The company advertised that the product can prevent, treat, or cure disease without competent and reliable scientific evidence.
FTC Act, 15 U.S.C. 41 et seq.Deceptive COVID-19 treatment claims can carry civil penalties of up to $43,792 per violation.
COVID-19 Consumer Protection Act, Section 1401, Division FF, Consolidated Appropriations Act, 2021, P.L. 116-260
What FDA wants
FDA asks the company to immediately stop selling unapproved products claimed to prevent or treat COVID-19 and, within 48 hours, email COVID-19-Task-Force-CDER@fda.hhs.gov with the steps taken and documentation to prevent recurrence.
Who should pay attention
- makers and sellers of COVID-19-related tinctures or supplements
- retailers and websites that list or link to such products
- quality teams reviewing disease claims on product labels and websites
This is a summary. Read the original letter on fda.gov.